Management of Kaposi's sarcoma in resource-limited settings in the era of HAART.
The introduction of highly active antiretroviral therapy (HAART) has changed the natural history of AIDS-associated Kaposi's sarcoma (KS). Although the use of HAART remains limited in low-resource settings, there are global initiatives to make these drugs available to several millions of HIV-infected persons. While there are multiple reports of KS regression during HAART with or without chemotherapy, there is little documentation on KS management in resource-limited settings. In this paper we review current KS treatments available worldwide and discuss the implications of the increased access to antiretrovirals for KS treatment strategies in resource-limited settings.
Lynen
Lut
L
Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium. llynen@itg.be
Zolfo
Maria
M
Huyst
Veerle
V
Louis
Francoise
F
Barnardt
Pieter
P
Van de Velde
Ann
A
De Schacht
Caroline
C
Colebunders
Robert
R
D023241:Antiretroviral Therapy, Highly Active; D003906:Developing Countries; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*